{"id":14581,"date":"2024-11-24T12:02:22","date_gmt":"2024-11-24T04:02:22","guid":{"rendered":"https:\/\/flcube.com\/?p=14581"},"modified":"2024-11-24T12:02:24","modified_gmt":"2024-11-24T04:02:24","slug":"three-senior-executives-of-henan-topfond-pharmaceutical-under-investigation","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=14581","title":{"rendered":"Three Senior Executives of Henan Topfond Pharmaceutical Under Investigation"},"content":{"rendered":"\n

On November 22, China General Technology (Group) Holding released three official announcements through its official channels, all concerning the investigation of senior executives at Henan Topfond Pharmaceutical Co., Ltd. (SHA: 600253). The details are as follows:<\/p>\n\n\n\n

    \n
  1. Investigation of Deputy General Manager Zhang Mingchun<\/strong>
    According to the disciplinary inspection and supervision team of China General Technology Group and the supervisory committee of Xuchang City, Henan Province: Zhang Mingchun, Deputy General Manager of Henan Topfond Pharmaceutical Co., Ltd, is suspected of serious disciplinary and legal violations and is currently under disciplinary review and supervisory investigation by the China General Technology Group’s disciplinary inspection and supervision team and the supervisory committee of Changge City, Xuchang, Henan Province.<\/li>\n\n\n\n
  2. Investigation of Former Deputy General Manager of the Preparation Division Zhang Junqing<\/strong>
    The disciplinary inspection and supervision team of China General Technology Group and the supervisory committee of Xuchang City, Henan Province report that Zhang Junqing, former Deputy General Manager of the Preparation Division at Henan Topfond Pharmaceutical Co., Ltd, is suspected of serious disciplinary and legal violations and is currently under disciplinary review and supervisory investigation by the same authorities.<\/li>\n\n\n\n
  3. Investigation of General Manager Assistant Zhang Erhua<\/strong>
    Zhang Erhua, General Manager Assistant at Henan Topfond Pharmaceutical Co., Ltd, is also suspected of serious disciplinary and legal violations and is currently under disciplinary review and supervisory investigation by the China General Technology Group’s disciplinary inspection and supervision team and the supervisory committee of Changge City, Xuchang, Henan Province.<\/li>\n<\/ol>\n\n\n\n

    Background on Henan Topfond Pharmaceutical<\/strong>
    Established in 1969, Henan Topfond Pharmaceutical is a large-scale comprehensive pharmaceutical enterprise specializing in the production and sales of finished preparations, chemical synthetic raw materials, and biological fermentation raw materials, as well as pharmaceutical operations. It integrates science, industry, and trade and was listed on the Shanghai Stock Exchange in December 2000. In August 2008, Henan Topfond Pharmaceutical joined China General Technology Group. In July 2013, it successfully merged with China Meheco Group Co., Ltd (SHA: 600056<\/a>) through a share exchange, formally coming under its management.-Fineline Info & Tech<\/a><\/p>\n\n\n\n

    <\/p>\n","protected":false},"excerpt":{"rendered":"

    On November 22, China General Technology (Group) Holding released three official announcements through its official…<\/p>\n","protected":false},"author":1,"featured_media":14584,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[2302,1404,2301,2300],"class_list":["post-14581","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-china-meheco-group","tag-sha-600056","tag-sha-600253","tag-topfond-pharmaceutical"],"yoast_head":"\nThree Senior Executives of Henan Topfond Pharmaceutical Under Investigation - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"On November 22, China General Technology (Group) Holding released three official announcements through its official channels, all concerning the investigation of senior executives at Henan Topfond Pharmaceutical Co., Ltd. (SHA: 600253). The details are as follows:\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=14581\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Three Senior Executives of Henan Topfond Pharmaceutical Under Investigation\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=14581\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-11-24T04:02:22+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-11-24T04:02:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/023-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"753\" \/>\n\t<meta property=\"og:image:height\" content=\"500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14581#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14581\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Three Senior Executives of Henan Topfond Pharmaceutical Under Investigation\",\"datePublished\":\"2024-11-24T04:02:22+00:00\",\"dateModified\":\"2024-11-24T04:02:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14581\"},\"wordCount\":341,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14581#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/023-1.png\",\"keywords\":[\"China Meheco Group\",\"SHA: 600056\",\"SHA: 600253\",\"Topfond Pharmaceutical\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14581#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14581\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=14581\",\"name\":\"Three Senior Executives of Henan Topfond Pharmaceutical Under Investigation - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14581#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14581#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/023-1.png\",\"datePublished\":\"2024-11-24T04:02:22+00:00\",\"dateModified\":\"2024-11-24T04:02:24+00:00\",\"description\":\"On November 22, China General Technology (Group) Holding released three official announcements through its official channels, all concerning the investigation of senior executives at Henan Topfond Pharmaceutical Co., Ltd. (SHA: 600253). The details are as follows:\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14581#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=14581\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14581#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/023-1.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/023-1.png\",\"width\":753,\"height\":500,\"caption\":\"China General Technology's Henan Topfond Pharmaceutical Faces Executive Investigations\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=14581#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Three Senior Executives of Henan Topfond Pharmaceutical Under Investigation\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Three Senior Executives of Henan Topfond Pharmaceutical Under Investigation - Insight, China's Pharmaceutical Industry","description":"On November 22, China General Technology (Group) Holding released three official announcements through its official channels, all concerning the investigation of senior executives at Henan Topfond Pharmaceutical Co., Ltd. (SHA: 600253). The details are as follows:","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=14581","og_locale":"en_US","og_type":"article","og_title":"Three Senior Executives of Henan Topfond Pharmaceutical Under Investigation","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=14581","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-11-24T04:02:22+00:00","article_modified_time":"2024-11-24T04:02:24+00:00","og_image":[{"width":753,"height":500,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/023-1.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=14581#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=14581"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Three Senior Executives of Henan Topfond Pharmaceutical Under Investigation","datePublished":"2024-11-24T04:02:22+00:00","dateModified":"2024-11-24T04:02:24+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=14581"},"wordCount":341,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=14581#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/023-1.png","keywords":["China Meheco Group","SHA: 600056","SHA: 600253","Topfond Pharmaceutical"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=14581#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=14581","url":"https:\/\/flcube.com\/?p=14581","name":"Three Senior Executives of Henan Topfond Pharmaceutical Under Investigation - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=14581#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=14581#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/023-1.png","datePublished":"2024-11-24T04:02:22+00:00","dateModified":"2024-11-24T04:02:24+00:00","description":"On November 22, China General Technology (Group) Holding released three official announcements through its official channels, all concerning the investigation of senior executives at Henan Topfond Pharmaceutical Co., Ltd. (SHA: 600253). The details are as follows:","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=14581#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=14581"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=14581#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/023-1.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/023-1.png","width":753,"height":500,"caption":"China General Technology's Henan Topfond Pharmaceutical Faces Executive Investigations"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=14581#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Three Senior Executives of Henan Topfond Pharmaceutical Under Investigation"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/023-1.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14581","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=14581"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14581\/revisions"}],"predecessor-version":[{"id":14585,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/14581\/revisions\/14585"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/14584"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=14581"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=14581"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=14581"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}